{"id":59281,"date":"2026-03-11T16:25:09","date_gmt":"2026-03-11T08:25:09","guid":{"rendered":"https:\/\/flcube.com\/?p=59281"},"modified":"2026-03-11T16:25:10","modified_gmt":"2026-03-11T08:25:10","slug":"abbiskos-absk061-wins-fda-rare-pediatric-disease-designation-fgfr2-3-inhibitor-targets-achondroplasia","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59281","title":{"rendered":"Abbisko&#8217;s ABSK061 Wins FDA Rare Pediatric Disease Designation \u2013 FGFR2\/3 Inhibitor Targets Achondroplasia"},"content":{"rendered":"\n<p><strong>Abbisko Therapeutics Co., Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2256:HKG\">HKG: 2256<\/a>) announced that <strong>ABSK061<\/strong>, its <strong>self-developed highly selective small-molecule FGFR2\/3 inhibitor<\/strong>, has received <strong>Rare Pediatric Disease (RPD) Designation<\/strong> from the <strong>U.S. FDA<\/strong> for the treatment of <strong>achondroplasia (ACH)<\/strong>. The <strong>potent, orally administered<\/strong> candidate, currently in <strong>Phase II studies for children aged 3-12<\/strong>, demonstrates <strong>significant target inhibition<\/strong>, <strong>favorable PK profiles<\/strong>, and <strong>strong safety advantages<\/strong> in preclinical models, positioning Abbisko to address the <strong>most common form of short-limbed dwarfism<\/strong> with a <strong>convenient therapeutic alternative<\/strong> to existing injectable therapies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>U.S. Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Designation<\/strong><\/td><td>Rare Pediatric Disease (RPD) Designation<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>ABSK061<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Highly selective small-molecule FGFR2\/3 inhibitor<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Achondroplasia (ACH)<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>Abbisko Therapeutics Co., Ltd (HKG: 2256) \u2013 self-developed<\/td><\/tr><tr><td><strong>Current Phase<\/strong><\/td><td>Phase II (children aged 3-12 years)<\/td><\/tr><tr><td><strong>Designation Date<\/strong><\/td><td>11\u202fMar\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>ABSK061 Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Targets<\/strong><\/td><td>Fibroblast growth factor receptor 2 and 3 (FGFR2\/3) \u2013 highly selective<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Inhibits FGFR3 signaling (gain-of-function mutation in achondroplasia) \u2192 normalizes bone growth plate chondrocyte proliferation and differentiation<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Small molecule (oral administration)<\/td><\/tr><tr><td><strong>Preclinical Profile<\/strong><\/td><td>\u2022 Significant target inhibition activity<br>\u2022 Favorable pharmacokinetic properties<br>\u2022 Strong safety advantage<\/td><\/tr><tr><td><strong>Clinical Advantage<\/strong><\/td><td>Oral convenience vs. injectable competitors; improved pediatric compliance<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Achondroplasia Pathophysiology:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>FGFR3 Mutation:<\/strong> Constitutively active receptor inhibits endochondral bone growth<\/li>\n\n\n\n<li><strong>Clinical Manifestations:<\/strong> Disproportionate short stature, foramen magnum stenosis, sleep apnea, spinal stenosis<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> No oral therapies; current standard requires daily\/weekly injections<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context-amp-market-opportunity\">Strategic Context &amp; Market Opportunity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Achondroplasia Prevalence<\/strong><\/td><td>~250,000 diagnosed patients globally; most common skeletal dysplasia (~1 in 20,000 births)<\/td><\/tr><tr><td><strong>Current Standard<\/strong><\/td><td>Vosoritide (BioMarin) \u2013 daily CNP analog injection; approved 2021 (U.S., EU)<\/td><\/tr><tr><td><strong>ABSK061 Differentiation<\/strong><\/td><td>Oral small molecule vs. peptide injection; potential for superior compliance and broader age access<\/td><\/tr><tr><td><strong>RPD Designation Value<\/strong><\/td><td>Priority review voucher eligibility upon approval; accelerates development timeline; FDA engagement support<\/td><\/tr><tr><td><strong>Pediatric Focus<\/strong><\/td><td>Phase II in 3-12 year olds (growth plate still open); potential for prophylactic treatment before skeletal complications develop<\/td><\/tr><tr><td><strong>Global Expansion<\/strong><\/td><td>U.S. RPD supports China NMPA priority pathway; EU orphan designation anticipated<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Competitor<\/th><th>Product<\/th><th>Mechanism<\/th><th>Route<\/th><th>Status<\/th><th>ABSK061 Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>BioMarin<\/strong><\/td><td>Vosoritide (Voxzogo)<\/td><td>C-type natriuretic peptide (CNP) analog<\/td><td>Daily SC injection<\/td><td>Approved (U.S., EU, 2021)<\/td><td>Oral convenience; small molecule manufacturing cost advantage<\/td><\/tr><tr><td><strong>BridgeBio<\/strong><\/td><td>Infigratinib (FGFR inhibitor)<\/td><td>Pan-FGFR inhibitor<\/td><td>Oral<\/td><td>Phase II (ACH)<\/td><td>ABSK061 FGFR2\/3 selectivity may improve safety vs. pan-FGFR<\/td><\/tr><tr><td><strong>Abbisko<\/strong><\/td><td><strong>ABSK061<\/strong><\/td><td><strong>Selective FGFR2\/3 inhibitor<\/strong><\/td><td><strong>Oral<\/strong><\/td><td><strong>Phase II; RPD Designation<\/strong><\/td><td><strong>First highly selective oral FGFR2\/3; potential best-in-class safety<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-outlook\">Development Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Timeline<\/th><th>Objectives<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase II (ONGOING)<\/strong><\/td><td>2025-2027<\/td><td>Efficacy in 3-12 year olds; height velocity; safety\/tolerability; dose optimization<\/td><\/tr><tr><td><strong>End-of-Phase II<\/strong><\/td><td>2027<\/td><td>Regulatory alignment with FDA; pivotal study design<\/td><\/tr><tr><td><strong>Phase III<\/strong><\/td><td>2027-2029<\/td><td>Registrational efficacy; bone growth endpoints; long-term safety<\/td><\/tr><tr><td><strong>NDA Filing<\/strong><\/td><td>2029-2030<\/td><td>U.S. priority review (RPD voucher); EU MAA; China NDA<\/td><\/tr><tr><td><strong>Label Expansion<\/strong><\/td><td>2030+<\/td><td>Adjacent FGFR-related skeletal dysplasias; hypochondroplasia<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Phase II outcomes, regulatory pathways, and competitive positioning for ABSK061 in achondroplasia. Actual results may differ due to clinical efficacy in pediatric population, safety profile vs. vosoritide, and manufacturing scale-up for rare disease supply.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that ABSK061, its self-developed highly selective small-molecule FGFR2\/3&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[186,921,24],"class_list":["post-59281","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-abbisko-therapeutics","tag-hkg-2256","tag-rare-orphan-disease-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Abbisko&#039;s ABSK061 Wins FDA Rare Pediatric Disease Designation \u2013 FGFR2\/3 Inhibitor Targets Achondroplasia - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that ABSK061, its self-developed highly selective small-molecule FGFR2\/3 inhibitor, has received Rare Pediatric Disease (RPD) Designation from the U.S. FDA for the treatment of achondroplasia (ACH). The potent, orally administered candidate, currently in Phase II studies for children aged 3-12, demonstrates significant target inhibition, favorable PK profiles, and strong safety advantages in preclinical models, positioning Abbisko to address the most common form of short-limbed dwarfism with a convenient therapeutic alternative to existing injectable therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59281\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Abbisko&#039;s ABSK061 Wins FDA Rare Pediatric Disease Designation \u2013 FGFR2\/3 Inhibitor Targets Achondroplasia\" \/>\n<meta property=\"og:description\" content=\"Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that ABSK061, its self-developed highly selective small-molecule FGFR2\/3 inhibitor, has received Rare Pediatric Disease (RPD) Designation from the U.S. FDA for the treatment of achondroplasia (ACH). The potent, orally administered candidate, currently in Phase II studies for children aged 3-12, demonstrates significant target inhibition, favorable PK profiles, and strong safety advantages in preclinical models, positioning Abbisko to address the most common form of short-limbed dwarfism with a convenient therapeutic alternative to existing injectable therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59281\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-11T08:25:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-11T08:25:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59281#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59281\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Abbisko&#8217;s ABSK061 Wins FDA Rare Pediatric Disease Designation \u2013 FGFR2\\\/3 Inhibitor Targets Achondroplasia\",\"datePublished\":\"2026-03-11T08:25:09+00:00\",\"dateModified\":\"2026-03-11T08:25:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59281\"},\"wordCount\":505,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Abbisko Therapeutics\",\"HKG: 2256\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59281#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59281\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59281\",\"name\":\"Abbisko's ABSK061 Wins FDA Rare Pediatric Disease Designation \u2013 FGFR2\\\/3 Inhibitor Targets Achondroplasia - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-11T08:25:09+00:00\",\"dateModified\":\"2026-03-11T08:25:10+00:00\",\"description\":\"Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that ABSK061, its self-developed highly selective small-molecule FGFR2\\\/3 inhibitor, has received Rare Pediatric Disease (RPD) Designation from the U.S. FDA for the treatment of achondroplasia (ACH). The potent, orally administered candidate, currently in Phase II studies for children aged 3-12, demonstrates significant target inhibition, favorable PK profiles, and strong safety advantages in preclinical models, positioning Abbisko to address the most common form of short-limbed dwarfism with a convenient therapeutic alternative to existing injectable therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59281#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59281\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59281#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Abbisko&#8217;s ABSK061 Wins FDA Rare Pediatric Disease Designation \u2013 FGFR2\\\/3 Inhibitor Targets Achondroplasia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Abbisko's ABSK061 Wins FDA Rare Pediatric Disease Designation \u2013 FGFR2\/3 Inhibitor Targets Achondroplasia - Insight, China&#039;s Pharmaceutical Industry","description":"Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that ABSK061, its self-developed highly selective small-molecule FGFR2\/3 inhibitor, has received Rare Pediatric Disease (RPD) Designation from the U.S. FDA for the treatment of achondroplasia (ACH). The potent, orally administered candidate, currently in Phase II studies for children aged 3-12, demonstrates significant target inhibition, favorable PK profiles, and strong safety advantages in preclinical models, positioning Abbisko to address the most common form of short-limbed dwarfism with a convenient therapeutic alternative to existing injectable therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59281","og_locale":"en_US","og_type":"article","og_title":"Abbisko's ABSK061 Wins FDA Rare Pediatric Disease Designation \u2013 FGFR2\/3 Inhibitor Targets Achondroplasia","og_description":"Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that ABSK061, its self-developed highly selective small-molecule FGFR2\/3 inhibitor, has received Rare Pediatric Disease (RPD) Designation from the U.S. FDA for the treatment of achondroplasia (ACH). The potent, orally administered candidate, currently in Phase II studies for children aged 3-12, demonstrates significant target inhibition, favorable PK profiles, and strong safety advantages in preclinical models, positioning Abbisko to address the most common form of short-limbed dwarfism with a convenient therapeutic alternative to existing injectable therapies.","og_url":"https:\/\/flcube.com\/?p=59281","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-11T08:25:09+00:00","article_modified_time":"2026-03-11T08:25:10+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59281#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59281"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Abbisko&#8217;s ABSK061 Wins FDA Rare Pediatric Disease Designation \u2013 FGFR2\/3 Inhibitor Targets Achondroplasia","datePublished":"2026-03-11T08:25:09+00:00","dateModified":"2026-03-11T08:25:10+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59281"},"wordCount":505,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Abbisko Therapeutics","HKG: 2256","Rare \/ orphan disease drugs"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59281#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59281","url":"https:\/\/flcube.com\/?p=59281","name":"Abbisko's ABSK061 Wins FDA Rare Pediatric Disease Designation \u2013 FGFR2\/3 Inhibitor Targets Achondroplasia - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-11T08:25:09+00:00","dateModified":"2026-03-11T08:25:10+00:00","description":"Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that ABSK061, its self-developed highly selective small-molecule FGFR2\/3 inhibitor, has received Rare Pediatric Disease (RPD) Designation from the U.S. FDA for the treatment of achondroplasia (ACH). The potent, orally administered candidate, currently in Phase II studies for children aged 3-12, demonstrates significant target inhibition, favorable PK profiles, and strong safety advantages in preclinical models, positioning Abbisko to address the most common form of short-limbed dwarfism with a convenient therapeutic alternative to existing injectable therapies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59281#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59281"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59281#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Abbisko&#8217;s ABSK061 Wins FDA Rare Pediatric Disease Designation \u2013 FGFR2\/3 Inhibitor Targets Achondroplasia"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59281","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59281"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59281\/revisions"}],"predecessor-version":[{"id":59284,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59281\/revisions\/59284"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59281"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59281"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59281"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}